Drug Profile

Janagliflozin - Sihuan Pharmaceutical Holdings Group

Alternative Names: SGLT2 inhibitor - Sihuan

Latest Information Update: 09 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sihuan Pharmaceutical Holdings Group
Class Antihypercalcaemics; Antihyperglycaemics; Glucosides
Mechanism of Action Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Registered Type 2 diabetes mellitus

Most Recent Events

19 Jan 2024 Registered for Type 2 diabetes mellitus (Combination therapy) in China (PO)
19 Jan 2024 Registered for Type 2 diabetes mellitus (Monotherapy) in China (PO)
07 Sep 2022 Janagliflozin is still in phase-III trials for Type 2 diabetes mellitus (Combination therapy, Treatment-experienced) in China (PO, Tablet) (NCT03851432)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com